



PALLA PHARMA

ASX ANNOUNCEMENT

Wednesday 23 December 2020

Palla Pharma Appoints UK Based Non-Executive Director

Palla Pharma Limited (ASX: PAL) (the “**Company**”) is pleased to announce that Iain Ross has agreed to join the Company’s Board of Directors effective Wednesday, December 23, 2020.

Mr Ross has over 40 years experience in the international pharmaceutical and biotechnology sectors, where he has held leadership positions as an executive and board member in numerous companies. Currently, he is Chairman of Silence Therapeutics plc (LSE/NASDAQ), Redx Pharma plc (LSE) and Kazia Limited (ASX/NASDAQ). Previously he has held senior executive positions at several companies including Sandoz AG, Fisons plc, Hoffmann La Roche AG and Celltech Group plc.

Palla Pharma Chairman, Simon Moore, said “we are excited to have a director with Iain’s unique combination of deep pharmaceutical industry and listed company board leadership join the Palla Pharma Board. The Company is about to embark on a significant new business expansion in the UK and European markets and having access to Iain’s insights through this period will be of significant value.”

Mr Ross commented “I am excited to join Palla Pharma at this important point of its development. I look forward to working with my Board colleagues and the Palla Pharma management team to help the Company realise its full potential.”

This announcement has been authorised for release by the Board of Palla Pharma Limited.

For more information please contact:

Simon Moore

Chairman
Palla Pharma Limited
+61 3 9301 0800

Brendan Middleton

Interim CEO
Palla Pharma Limited
+61 3 9301 0800

Adrian Mulcahy

Investor Relations
Market Eye
+61 438 630 422
ir@pallapharma.com

About Palla Pharma Limited:

Palla Pharma Limited (ASX:PAL) is a vertically integrated opiate manufacturer from poppy straw growing through to tableting production. Palla Pharma has developed an innovative, efficient and environmentally sustainable opiate manufacturing process based on a novel water-based extraction technology. The company is one of six licensed opiate producers globally, and one of three fully integrated suppliers from opiate extraction through to tableting production delivering on its strategy to secure access to regulated downstream narcotics markets by leveraging its production cost advantage.

Palla Pharma Limited

PO Box 2139 Melbourne, VIC 3001, Australia

T +61 3 9301 0800 / F +61 3 9301 0899 / W pallapharma.com / E info@pallapharma.com